Abbott, Cordis-backed study challenges stent options for coronary bifurcation lesions

An international clinical trial funded, in part, by Abbott ($ABT) and Johnson & Johnson's ($JNJ) Cordis concluded that using a two-stent technique to treat coronary bifurcation lesions with a large stenotic side branch didn't work any better than a provisional stenting approach. The Nordic-Baltic Bifurcation IV study looked at 450 patients with coronary bifurcation lesions, randomized 1:1. Surgeons used a provisional strategy on one group (stenting of the main vessel and provisional stenting of the side branch) and a complex two-stent strategy on the other (planned stenting for both the main vessel and side branch). Rates of major adverse cardiac events were about the same for both groups, the researchers said. But longer and more complex procedures for the two-stent group didn't lead to more procedure-related heart attacks. Researchers presented their findings at the 25th annual Transcatheter Cardiovascular Therapeutics scientific symposium in San Francisco. Item

Suggested Articles

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.

Cybernet Manufacturing, maker of medical-grade computer monitors, has unveiled a new, large touchscreen designed to protect against infections.

A startup has raised $12 million to fund its real-time system for monitoring patients undergoing dialysis at home and calling in complications.